VivoSeq
Other

Total Hip Replacement

0

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Total Hip Replacement is an early-stage landscape with 0 programs across 6 companies. The most active players are Bayer, Daiichi Sankyo, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

30

clinical trials

Completed22 · 73%
Terminated4 · 13%
Unknown status2 · 7%
Withdrawn1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

30 trials

Prehabilitation in Older People Undergoing Total Hip Replacement
Not yet recruiting·UUniversidad de La Frontera·N/A·NCT07048080·70 enrolled
Effectiveness of PENG Block Combined to LFCN Block on the Quality of Recovery After Total Hip Replacement
Completed·—·N/A·NCT04245280·74 enrolled
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump
Completed·AAlza Corporation, DE, USA·Phase 3·NCT00264485·799 enrolled
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT00107900·606 enrolled
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Completed·Bayer logoBayer·Phase 2·NCT00396786·877 enrolled
Minimal Opioid Use After Total Hip Replacement (THR)
Completed·HHospital for Special Surgery, New York·Phase 4·NCT03090152·180 enrolled
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT01369511·400 enrolled
Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Hemostasis in Subjects Undergoing Total Hip Replacement
Completed·BBaxter Healthcare Corporation·Phase 3·NCT00161902
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Completed·Bayer logoBayer·Phase 2·NCT00398905·726 enrolled
Dose-confirmatory Bridging Study in Total Hip Replacement
Completed·Bayer logoBayer·Phase 3·NCT01205932·402 enrolled
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
Completed·Sanofi logoSanofi·Phase 3·NCT00349180·156 enrolled
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
Completed·Bayer logoBayer·Phase 3·NCT00329628·4,541 enrolled
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
Completed·GSK logoGSK·Phase 3·NCT00320398·114 enrolled
Comparison of Local Anesthetic Dose in PENG Block Performed in Total Hip Replacement Operations
Completed·IIstanbul University·N/A·NCT04900116·84 enrolled
Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement
Completed·Bayer logoBayer·Phase 3·NCT00668031·359 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)